Decapitating non-physiological NFκB activity and repressing anti-apoptotic BCL2 signaling

08/04/2016

A potential tool for novel targeted therapeutic strategies. Diffuse large B cell lymphoma - the most common and aggressive blood cancer in the Western world - remains a clinical challenge. Christian Reinhardt and Christian Pallasch highlighted

together with their co-workers, the recent developments referring to therapeutic strategies and made suggestions for further tool development as well as the design and stratification of future clinical trials. In particular, the genomic and biological features of the ABC-DLBC were called to attention.  

Currently, a picture is emerging which suggests that ABC-DLBCL critically depends on sustained activity of the NFκB pathway, which, among others, is achieved through numerous distinct genetic aberrations, including CD79A/B-, CARD11- and MYD88 mutations.  

The researchers state that the genomic understanding of the disease will provide the basis for the development and validation of novel targeted therapeutic intervention strategies that aim at decapitating non-physiological NFκB activity and repressing anti-apoptotic BCL2 signaling.


The review is published in the prestigious European Journal of Haematology:
Rewired NFκB signaling as a potentially actionable feature of activated B cell-like diffuse large B cell lymphoma.
Knittel G, Liedgens P, Korovkina D, Pallasch CP, Reinhardt HC.
Eur J Haematol. 2016 Aug 16. doi: 10.1111/ejh.12792. [Epub ahead of print] Review.